The Dermavant Sciences logo.

Featured Searches

VTAMA® (tapinarof) cream, 1%

In the News

Careers

Leadership Team

Most Searched Tags

Clinical Trials Field Medical Director Compliance Program Medical Affairs Culture
Search Results for: Clinical Trials
Post Plaque Psoriasis

Dermavant to Present New Positive Data from Phase 4, Open Label Trial of VTAMA® (tapinarof) Cream, 1% for Intertriginous Plaque Psoriasis in Adults and Multiple Clinical Trials of VTAMA cream at the 2023 Fall Clinical Dermatology Conference

– Six posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two years old – LONG BEACH, Calif., and BASEL, Switzerland, October 16, 2023 – Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, […]
Page

Clinical Trials
Post Atopic Dermatitis

Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA® (tapinarof) cream, 1% for the treatment of Atopic Dermatitis in Adults and Children as Young as 2 years old

– ADORING 1 and 2 trials evaluating VTAMA cream in atopic dermatitis fully enrolled, with topline data expected from the first study in March 2023 and the second study in May 2023 –  – Dermavant recently published highly favorable results from a pediatric maximal usage (MUPK) study of VTAMA cream in atopic dermatitis (AD) demonstrating […]
Post Atopic Dermatitis

Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference

– Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two – LONG BEACH, Calif., and BASEL, Switzerland, Oct. 13, 2022 — Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced […]
Post Plaque Psoriasis

Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis

Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action Dermavant Expects to Announce Results from PSOARING 1 and PSOARING 2 in 2H 2020 A Long-Term Safety Study for Tapinarof Continues Enrolling Patients LONG BEACH, Calif. and BASEL, Switzerland, Apr. 2, 2020—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today […]
Post Atopic Dermatitis

Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and ADORING 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 American Academy of Dermatology Annual Meeting

— VTAMA cream demonstrated statistically significant efficacy in adults and children down to 2 years of age with atopic dermatitis, in a diverse population comprised of approximately 50% of patients with skin of color — — In ADORING 1 and ADORING 2, 57.1% and 58.1% of patients, respectively, with Fitzpatrick skin type (IV, V, VI) […]
Post Atopic Dermatitis

Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 American Academy of Dermatology Annual Meeting

— Four poster presentations, including two oral presentations, will highlight the clinical data for VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age and older — LONG BEACH, Calif., and BASEL, Switzerland, March 1, 2024 – Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics […]
Post Plaque Psoriasis

Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference

— Notably, 82.8% of adult patients achieved an intertriginous Physician Global Assessment (iPGA) Score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at Week 12, demonstrating compelling efficacy. — — Patients experienced a rapid onset of efficacy, with iPGA success occurring, as early as 2 weeks, with a median time […]
Post Atopic Dermatitis

Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children as Young as 2 Years Old with Atopic Dermatitis at the 2023 EADV Congress

– Two late breaking oral presentations will highlight the efficacy and rapid onset of itch relief of VTAMA cream for the treatment of adults and children as young as two years of age with moderate to severe atopic dermatitis – LONG BEACH, Calif., and BASEL, Switzerland, October 6, 2023 – Dermavant Sciences, a clinical-stage biopharmaceutical company […]
Post Atopic DermatitisPlaque Psoriasis

Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference  

– Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study (MUPK) in atopic dermatitis – LONG BEACH, Calif., and BASEL, Switzerland, January 12, 2023 — Dermavant Sciences, a biopharmaceutical company dedicated to developing and […]

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

Important Safety Information

Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.